Loading…
Comparison of Three Lateral Flow Immunoassay Formats for the Detection of Antibodies against the SARS-CoV-2 Antigen
Reliable detection of specific antibodies against pathogens by lateral flow immunoassay (LFIA) greatly depends on the composition of the detectable complex and the order of its assembly. We compared three LFIA formats for revealing anti-SARS-CoV-2 antibodies in sera with the following detected compl...
Saved in:
| Published in: | Biosensors (Basel) 2023-07, Vol.13 (7), p.750 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c546t-4ad67e5551651ff0cafd0f4e9a07dd0c073b6c96a2970e767ff6cf2649ae6f83 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c546t-4ad67e5551651ff0cafd0f4e9a07dd0c073b6c96a2970e767ff6cf2649ae6f83 |
| container_end_page | |
| container_issue | 7 |
| container_start_page | 750 |
| container_title | Biosensors (Basel) |
| container_volume | 13 |
| creator | Sotnikov, Dmitriy V Byzova, Nadezhda A Zherdev, Anatoly V Xu, Youchun Dzantiev, Boris B |
| description | Reliable detection of specific antibodies against pathogens by lateral flow immunoassay (LFIA) greatly depends on the composition of the detectable complex and the order of its assembly. We compared three LFIA formats for revealing anti-SARS-CoV-2 antibodies in sera with the following detected complexes in the analytical zone of the strip: antigen-antibodies-labeled immunoglobulin-binding protein (Scheme A); antigen-antibodies-labeled antigen (Scheme B); and immunoglobulin-binding protein-antibodies-labeled antigen (Scheme C). The lowest detection limit was observed for Scheme C, and was equal to 10 ng/mL of specific humanized monoclonal antibodies. When working with pooled positive sera, Scheme C had a detection limit 15 times lower than Scheme B and 255 times lower than Scheme A. Due to the high sensitivity of Scheme C, its application for the panel of human sera (n = 22) demonstrated 100% diagnostic specificity and sensitivity. These consistent results be useful for designing the format of LFIA serodiagnosis for other diseases. |
| doi_str_mv | 10.3390/bios13070750 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1c9b98e684194a02b5a8d9ce40c9b67d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A758880022</galeid><doaj_id>oai_doaj_org_article_1c9b98e684194a02b5a8d9ce40c9b67d</doaj_id><sourcerecordid>A758880022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c546t-4ad67e5551651ff0cafd0f4e9a07dd0c073b6c96a2970e767ff6cf2649ae6f83</originalsourceid><addsrcrecordid>eNptks-LEzEUgAdR3GXdm2cZ8OLBWfNrkslJSrVuoSC4xWvIZF7alJlJTdKV_e9N2921FZNDwsv3vvAeryjeYnRDqUSfWucjpkggUaMXxSVBQlacCvby5H5RXMe4QXkJJiQVr4sLmnGGWXNZxKkftjq46MfS23K5DgDlQicIui9nvf9dzodhN3odo34oZz4MOsXS-lCmNZRfIIFJ7pg7GZNrfecglnql3RjTgbmb_Lirpv5nRQ7ECsY3xSur-wjXj-dVsZx9XU5vq8X3b_PpZFGZmvFUMd1xAXVdY15ja5HRtkOWgdRIdB0ySNCWG8k1kQKB4MJabizhTGrgtqFXxfyo7bzeqG1wgw4PymunDgEfVkqH5EwPChvZygZ4w7BkGpG21k0nDTCUH7josuvz0bXdtQN0BsaUG3QmPX8Z3Vqt_L3CiAouJcqGD4-G4H_tICY1uGig7_UIfhcVaRhDkhBMMvr-H3Tjd2HMrdpTFFGChfhLrXSuwI3W54_NXqomom6aBiGyd938h8q7g8EZP4J1OX6W8PGYYIKPMYB9LhIjtZ85dTpzGX932phn-GnC6B8RRNCY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2843032177</pqid></control><display><type>article</type><title>Comparison of Three Lateral Flow Immunoassay Formats for the Detection of Antibodies against the SARS-CoV-2 Antigen</title><source>PubMed Central (Open Access)</source><source>Publicly Available Content Database</source><source>Coronavirus Research Database</source><creator>Sotnikov, Dmitriy V ; Byzova, Nadezhda A ; Zherdev, Anatoly V ; Xu, Youchun ; Dzantiev, Boris B</creator><creatorcontrib>Sotnikov, Dmitriy V ; Byzova, Nadezhda A ; Zherdev, Anatoly V ; Xu, Youchun ; Dzantiev, Boris B</creatorcontrib><description>Reliable detection of specific antibodies against pathogens by lateral flow immunoassay (LFIA) greatly depends on the composition of the detectable complex and the order of its assembly. We compared three LFIA formats for revealing anti-SARS-CoV-2 antibodies in sera with the following detected complexes in the analytical zone of the strip: antigen-antibodies-labeled immunoglobulin-binding protein (Scheme A); antigen-antibodies-labeled antigen (Scheme B); and immunoglobulin-binding protein-antibodies-labeled antigen (Scheme C). The lowest detection limit was observed for Scheme C, and was equal to 10 ng/mL of specific humanized monoclonal antibodies. When working with pooled positive sera, Scheme C had a detection limit 15 times lower than Scheme B and 255 times lower than Scheme A. Due to the high sensitivity of Scheme C, its application for the panel of human sera (n = 22) demonstrated 100% diagnostic specificity and sensitivity. These consistent results be useful for designing the format of LFIA serodiagnosis for other diseases.</description><identifier>ISSN: 2079-6374</identifier><identifier>EISSN: 2079-6374</identifier><identifier>DOI: 10.3390/bios13070750</identifier><identifier>PMID: 37504148</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibodies ; Antibodies, Viral ; Antigens ; COVID-19 ; COVID-19 - diagnosis ; Disease transmission ; Health aspects ; Humans ; immune complexes ; Immunoassay ; Immunoassay - methods ; immunochromatography ; Immunoglobulins ; Measurement ; Monoclonal antibodies ; Nanoparticles ; Pathogens ; Proteins ; SARS-CoV-2 ; Sensitivity ; Sensitivity and Specificity ; serodiagnostics ; serum testing ; Severe acute respiratory syndrome coronavirus 2 ; Viral antibodies ; Viral antigens</subject><ispartof>Biosensors (Basel), 2023-07, Vol.13 (7), p.750</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c546t-4ad67e5551651ff0cafd0f4e9a07dd0c073b6c96a2970e767ff6cf2649ae6f83</citedby><cites>FETCH-LOGICAL-c546t-4ad67e5551651ff0cafd0f4e9a07dd0c073b6c96a2970e767ff6cf2649ae6f83</cites><orcidid>0000-0003-4008-4918 ; 0000-0002-4993-0685 ; 0000-0003-3008-2839</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2843032177/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2843032177?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74284,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37504148$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sotnikov, Dmitriy V</creatorcontrib><creatorcontrib>Byzova, Nadezhda A</creatorcontrib><creatorcontrib>Zherdev, Anatoly V</creatorcontrib><creatorcontrib>Xu, Youchun</creatorcontrib><creatorcontrib>Dzantiev, Boris B</creatorcontrib><title>Comparison of Three Lateral Flow Immunoassay Formats for the Detection of Antibodies against the SARS-CoV-2 Antigen</title><title>Biosensors (Basel)</title><addtitle>Biosensors (Basel)</addtitle><description>Reliable detection of specific antibodies against pathogens by lateral flow immunoassay (LFIA) greatly depends on the composition of the detectable complex and the order of its assembly. We compared three LFIA formats for revealing anti-SARS-CoV-2 antibodies in sera with the following detected complexes in the analytical zone of the strip: antigen-antibodies-labeled immunoglobulin-binding protein (Scheme A); antigen-antibodies-labeled antigen (Scheme B); and immunoglobulin-binding protein-antibodies-labeled antigen (Scheme C). The lowest detection limit was observed for Scheme C, and was equal to 10 ng/mL of specific humanized monoclonal antibodies. When working with pooled positive sera, Scheme C had a detection limit 15 times lower than Scheme B and 255 times lower than Scheme A. Due to the high sensitivity of Scheme C, its application for the panel of human sera (n = 22) demonstrated 100% diagnostic specificity and sensitivity. These consistent results be useful for designing the format of LFIA serodiagnosis for other diseases.</description><subject>Antibodies</subject><subject>Antibodies, Viral</subject><subject>Antigens</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>Disease transmission</subject><subject>Health aspects</subject><subject>Humans</subject><subject>immune complexes</subject><subject>Immunoassay</subject><subject>Immunoassay - methods</subject><subject>immunochromatography</subject><subject>Immunoglobulins</subject><subject>Measurement</subject><subject>Monoclonal antibodies</subject><subject>Nanoparticles</subject><subject>Pathogens</subject><subject>Proteins</subject><subject>SARS-CoV-2</subject><subject>Sensitivity</subject><subject>Sensitivity and Specificity</subject><subject>serodiagnostics</subject><subject>serum testing</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viral antibodies</subject><subject>Viral antigens</subject><issn>2079-6374</issn><issn>2079-6374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks-LEzEUgAdR3GXdm2cZ8OLBWfNrkslJSrVuoSC4xWvIZF7alJlJTdKV_e9N2921FZNDwsv3vvAeryjeYnRDqUSfWucjpkggUaMXxSVBQlacCvby5H5RXMe4QXkJJiQVr4sLmnGGWXNZxKkftjq46MfS23K5DgDlQicIui9nvf9dzodhN3odo34oZz4MOsXS-lCmNZRfIIFJ7pg7GZNrfecglnql3RjTgbmb_Lirpv5nRQ7ECsY3xSur-wjXj-dVsZx9XU5vq8X3b_PpZFGZmvFUMd1xAXVdY15ja5HRtkOWgdRIdB0ySNCWG8k1kQKB4MJabizhTGrgtqFXxfyo7bzeqG1wgw4PymunDgEfVkqH5EwPChvZygZ4w7BkGpG21k0nDTCUH7josuvz0bXdtQN0BsaUG3QmPX8Z3Vqt_L3CiAouJcqGD4-G4H_tICY1uGig7_UIfhcVaRhDkhBMMvr-H3Tjd2HMrdpTFFGChfhLrXSuwI3W54_NXqomom6aBiGyd938h8q7g8EZP4J1OX6W8PGYYIKPMYB9LhIjtZ85dTpzGX932phn-GnC6B8RRNCY</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Sotnikov, Dmitriy V</creator><creator>Byzova, Nadezhda A</creator><creator>Zherdev, Anatoly V</creator><creator>Xu, Youchun</creator><creator>Dzantiev, Boris B</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4008-4918</orcidid><orcidid>https://orcid.org/0000-0002-4993-0685</orcidid><orcidid>https://orcid.org/0000-0003-3008-2839</orcidid></search><sort><creationdate>20230701</creationdate><title>Comparison of Three Lateral Flow Immunoassay Formats for the Detection of Antibodies against the SARS-CoV-2 Antigen</title><author>Sotnikov, Dmitriy V ; Byzova, Nadezhda A ; Zherdev, Anatoly V ; Xu, Youchun ; Dzantiev, Boris B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c546t-4ad67e5551651ff0cafd0f4e9a07dd0c073b6c96a2970e767ff6cf2649ae6f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Antibodies, Viral</topic><topic>Antigens</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>Disease transmission</topic><topic>Health aspects</topic><topic>Humans</topic><topic>immune complexes</topic><topic>Immunoassay</topic><topic>Immunoassay - methods</topic><topic>immunochromatography</topic><topic>Immunoglobulins</topic><topic>Measurement</topic><topic>Monoclonal antibodies</topic><topic>Nanoparticles</topic><topic>Pathogens</topic><topic>Proteins</topic><topic>SARS-CoV-2</topic><topic>Sensitivity</topic><topic>Sensitivity and Specificity</topic><topic>serodiagnostics</topic><topic>serum testing</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viral antibodies</topic><topic>Viral antigens</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sotnikov, Dmitriy V</creatorcontrib><creatorcontrib>Byzova, Nadezhda A</creatorcontrib><creatorcontrib>Zherdev, Anatoly V</creatorcontrib><creatorcontrib>Xu, Youchun</creatorcontrib><creatorcontrib>Dzantiev, Boris B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals (Open Access)</collection><jtitle>Biosensors (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sotnikov, Dmitriy V</au><au>Byzova, Nadezhda A</au><au>Zherdev, Anatoly V</au><au>Xu, Youchun</au><au>Dzantiev, Boris B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Three Lateral Flow Immunoassay Formats for the Detection of Antibodies against the SARS-CoV-2 Antigen</atitle><jtitle>Biosensors (Basel)</jtitle><addtitle>Biosensors (Basel)</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>13</volume><issue>7</issue><spage>750</spage><pages>750-</pages><issn>2079-6374</issn><eissn>2079-6374</eissn><abstract>Reliable detection of specific antibodies against pathogens by lateral flow immunoassay (LFIA) greatly depends on the composition of the detectable complex and the order of its assembly. We compared three LFIA formats for revealing anti-SARS-CoV-2 antibodies in sera with the following detected complexes in the analytical zone of the strip: antigen-antibodies-labeled immunoglobulin-binding protein (Scheme A); antigen-antibodies-labeled antigen (Scheme B); and immunoglobulin-binding protein-antibodies-labeled antigen (Scheme C). The lowest detection limit was observed for Scheme C, and was equal to 10 ng/mL of specific humanized monoclonal antibodies. When working with pooled positive sera, Scheme C had a detection limit 15 times lower than Scheme B and 255 times lower than Scheme A. Due to the high sensitivity of Scheme C, its application for the panel of human sera (n = 22) demonstrated 100% diagnostic specificity and sensitivity. These consistent results be useful for designing the format of LFIA serodiagnosis for other diseases.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37504148</pmid><doi>10.3390/bios13070750</doi><orcidid>https://orcid.org/0000-0003-4008-4918</orcidid><orcidid>https://orcid.org/0000-0002-4993-0685</orcidid><orcidid>https://orcid.org/0000-0003-3008-2839</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2079-6374 |
| ispartof | Biosensors (Basel), 2023-07, Vol.13 (7), p.750 |
| issn | 2079-6374 2079-6374 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_1c9b98e684194a02b5a8d9ce40c9b67d |
| source | PubMed Central (Open Access); Publicly Available Content Database; Coronavirus Research Database |
| subjects | Antibodies Antibodies, Viral Antigens COVID-19 COVID-19 - diagnosis Disease transmission Health aspects Humans immune complexes Immunoassay Immunoassay - methods immunochromatography Immunoglobulins Measurement Monoclonal antibodies Nanoparticles Pathogens Proteins SARS-CoV-2 Sensitivity Sensitivity and Specificity serodiagnostics serum testing Severe acute respiratory syndrome coronavirus 2 Viral antibodies Viral antigens |
| title | Comparison of Three Lateral Flow Immunoassay Formats for the Detection of Antibodies against the SARS-CoV-2 Antigen |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A06%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Three%20Lateral%20Flow%20Immunoassay%20Formats%20for%20the%20Detection%20of%20Antibodies%20against%20the%20SARS-CoV-2%20Antigen&rft.jtitle=Biosensors%20(Basel)&rft.au=Sotnikov,%20Dmitriy%20V&rft.date=2023-07-01&rft.volume=13&rft.issue=7&rft.spage=750&rft.pages=750-&rft.issn=2079-6374&rft.eissn=2079-6374&rft_id=info:doi/10.3390/bios13070750&rft_dat=%3Cgale_doaj_%3EA758880022%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c546t-4ad67e5551651ff0cafd0f4e9a07dd0c073b6c96a2970e767ff6cf2649ae6f83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2843032177&rft_id=info:pmid/37504148&rft_galeid=A758880022&rfr_iscdi=true |